Intega Consulting’s Post

At best, provider institutions and pharmaceutical companies are frenemies. At worst, they are adversaries. Either way, the acrimony isn’t working for anyone, especially patients. But, Key Account Managers (KAMs) can play a pivotal role in turning the current situation from a lose-lose-lose proposition to one where providers, pharmaceutical companies, and patients all win. In this article, my colleagues highlight four strategic areas where KAMs can make a difference. #OWHealth

At best, provider institutions and pharmaceutical companies are frenemies. At worst, they are adversaries. Either way, the acrimony isn’t working for anyone, especially patients. But, Key Account Managers (KAMs) can play a pivotal role in turning the current situation from a lose-lose-lose proposition to one where providers, pharmaceutical companies, and patients all win. In this article, my colleagues highlight four strategic areas where KAMs can make a difference. #OWHealth

A DECADE OF INNOVATION ▸ Last week, Akesa and esteemed guests gathered to mark an extraordinary decade-long journey of dedication, innovation, and collaboration in pushing the boundaries of what's possible in clinical trial supply and pharmaceutical services. Our 10-year anniversary celebration was an opportunity to honour the collective efforts that have shaped our success, and to share Akesa’s strategic vision for the years ahead. Insights from directors Chris Zigomanis, Con Konstantopoulos and George Vlachos, together with impromptu speeches from valued suppliers and customers, underscored the essence of Akesa's mission: to pioneer with purpose, navigate challenges with resilience, and embrace opportunities with innovation. To our team, partners, customers, and all who have supported us along the way – your trust in Akesa has been the foundation of our accomplishments. Whether you joined us in celebrating in person or in spirit, we extend our heartfelt thanks for your ongoing support. Here's to the next decade of making a difference, together. #Akesa #LetDiscoveryLive #10YearsOfInnovation #ClinicalTrials #Pharmaceuticals #AnniversaryCelebration 📷: Chris Zigomanis, Con Konstantopoulos, George Vlachos, Halifi Ismail, Arishma Narayan, Julian Battistella, May Mitropoulos, Elisha Hall, Sihara Yamile Gonzalez Gonzalez, Patrick Davies, Karen Montgomery-Douglas, Mayank Maini

With double of the US population and universal healthcare access, Europe represents the second largest healthcare market in the world.    Today we bid farewell to our “Think about Europe” series of posts; through which we described the challenges and commercial opportunity that Europe represents for US-based pharmaceutical and biotech companies looking to expand their footprint >> find link to our articles here: https://lnkd.in/dtbB3CAM   The Cogentia team are well prepared to help you identify potential pitfalls for the European market and bring much needed treatments to patients across Europe.    #marketaccess #europe #HEOR

Navigating the realm of pharmaceutical exclusivity, this report delves into the latest developments featuring Bristol Myers Squibb, Biogen, Novo Nordisk, Astellas, and Novartis, showcasing their blockbuster medications and storied histories. Additionally, it sheds light on companies such as PTC Therapeutics, Organon, Supernus, CSL, and Bausch + Lomb, who are poised to encounter significant potential losses in exclusivity throughout 2024. Embark on a journey through the evolving landscape of pharmaceuticals, tracing the path from exclusivity to new horizons. https://lnkd.in/dhvbzQnp Making changes? Let's have a conversation. At #SECORA our methodologies are proven in success to accelerate operational distinction in highly regulated industries. We have methods that address: Process Design & Optimisation, Lean & CIP Implementation, Project & Launch Management, Organization Development, Restructuring and Sustainability, and Supply Chain & Development. Visit www.secora.de for more info.

At best, provider institutions and pharmaceutical companies are frenemies. At worst, they are adversaries. Either way, the acrimony isn’t working for anyone, especially patients. But, Key Account Managers (KAMs) can play a pivotal role in turning the current situation from a lose-lose-lose proposition to one where providers, pharmaceutical companies, and patients all win. In this article, my colleagues highlight four strategic areas where KAMs can make a difference. #OWHealth

At best, provider institutions and pharmaceutical companies are frenemies. At worst, they are adversaries. Either way, the acrimony isn’t working for anyone, especially patients. But, Key Account Managers (KAMs) can play a pivotal role in turning the current situation from a lose-lose-lose proposition to one where providers, pharmaceutical companies, and patients all win. In this article, my colleagues highlight four strategic areas where KAMs can make a difference. #OWHealth

More and more it feels like our clients are coming to us with questions on how to modernize their commercial sales model. Based on research we did with a variety of US provider institutions, we detail here how Key Account Managers (KAMs) can play a pivotal role in turning the current situation from a lose-lose-lose proposition to one where providers, pharmaceutical companies, and patients all win.

🚀 Pharma Execs Alert! 🚀 Time's relentless march means one thing for pharma execs: the urgency of new launches to offset revenue lost to the patent cliff. Consider Humira, a global sales titan peaking at over $21 billion. Despite its success, it faced biosimilars in 2023, leading to a sharp decline. At Fierce Pharma, we've compiled the top drugs set to face this fate in 2024. From Bristol Myers Squibb to Novartis, these blockbusters are on the radar. Navigating legal and regulatory uncertainties, our report uses a mix of company filings and outside sources for reliability. Get ahead with insights from Corporate Pharmacy Services, Biospace, and OptumRx. See the full report👉 https://ow.ly/CPxf50QQBiR Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotech #FierceLifeSciencesEvents #FiercePharma #WeAreFierce

With double of the US population and universal healthcare access, Europe represents the second largest healthcare market in the world.    Today we bid farewell to our “Think about Europe” series of posts; through which we described the challenges and commercial opportunity that Europe represents for US-based pharmaceutical and biotech companies looking to expand their footprint.    The topics we have discussed during the campaign are linked here and outlined below >> https://lnkd.in/dtbB3CAM   Our overall recommendations to manufacturers are: A) Think about Europe early in the clinical development process to maximise the European opportunity, we recommend it to be no later than in Phase II clinical trials.    B) Understand country level reimbursement processes and pricing potential to help decision-makers think more intelligently about resource allocation in the long term    c) Consider engaging with an experienced partner for European market access to mitigate the potential commercialisation challenges down the road.   The Cogentia team are well prepared to help you identify potential pitfalls for the European market and bring much needed treatments to patients across Europe.    #marketaccess #europe #HEOR